View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 24, 2020updated 25 Feb 2020 9:15am

Animal testing begins for first novel coronavirus vaccines in China

The initial recombinant protein vaccines have produced antibodies during preclinical testing in mice, said Zhejiang Science and Technology department official at a press conference.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Follow the latest updates of the outbreak on our timeline.

The initial recombinant protein vaccines have produced antibodies during preclinical testing in mice, said Zhejiang Science and Technology department official at a press conference.

The department’s deputy director Song Zhiheng added that mRNA vaccines have also advanced into the animal experiment stage.

Animal testing for recombinant adenovirus vector vaccines could be initiated soon, while virus strains selection has progressed into the fourth generation.

Commenting on the progress, Song said: “At present, researchers are racing against the clock and working hard to overcome difficulties.

“But it is also important to realise that due to the relatively long period of vaccine development, scientific laws must be respected and a scientific, rigorous and safe research process must be followed.

Earlier this month, Imperial College London researchers in the UK started animal testing a novel coronavirus vaccine. This announcement was followed by the progress of Serum Institute of India and Codagenix’s vaccine candidate into preclinical phase.


See all Coronavirus vaccines and drugs in the pipeline


At a meeting held on 11 and 12 February in Geneva, World Health Organization (WHO) director-general Dr Tedros Adhanom Ghebreyesus said that a vaccine for the novel coronavirus may be available in 18 months.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology